Topical delivery of Ranibizumab for non-invasive treatment of retinal disease (360G-Wellcome-106942_Z_15_Z)

£1,666,193

Anti-Vascular Endothelial Growth Factor (anti-VEGF) agents have revolutionisedthe management of age-related macular degeneration (AMD). Ranibizumab (Lucentis) is NICE-approved and the most common anti-VEGF therapy; however, its administration is very expensive, requiring repeated monthly and long-termhospital-based administration (NHS estimate £85million/year). Intravitreal injections have significant risks of blinding complications including endophthalmitis, retinal detachment, cataract and uveitis, and are unappealingto patients. There is thus a strong and growing unmet need for Lucentis treatments to be non-invasive, easy to administer and less expensive. The UCL Drug Delivery System (UDDS) is a novel ocular nanoparticle drug delivery system developed in the Cordeiro laboratory, which has already been used to successfully deliver topically several molecules to the back of the rabbit eye, including bevacizumab (Avastin). The aim of this project is to develop a UDDS-Lucentis formulation for patientsto replace monthly hospital- administered intraocular Lucentis injections with

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 1666193
Applicant Surname Cordeiro
Approval Committee Health Innovation Challenge Fund
Award Date 2015-04-16T00:00:00+00:00
Financial Year 2014/15
Grant Programme: Title Health Innovation Challenge Fund
Has the grant transferred? No
Internal ID 106942/Z/15/Z
Lead Applicant Prof Francesca Cordeiro
Planned Dates: End Date 2026-07-04T00:00:00+00:00
Planned Dates: Start Date 2016-02-05T00:00:00+00:00
Recipient Org: City London
Recipient Org: Country United Kingdom
Region London
Research conducted at multiple locations? No
Total amount including partnership funding 1666193